Alpha Lipoic Acid and Visceral Fat: UK Guide

Alpha lipoic acid and visceral fat have attracted growing interest as researchers explore whether this naturally occurring antioxidant can influence fat distribution around the abdominal organs. ALA is produced in small amounts by the body, found in foods such as spinach and broccoli, and widely available as a food supplement in the UK. Its roles in mitochondrial energy metabolism, insulin sensitivity, and oxidative stress reduction have led to questions about whether supplementation might help reduce metabolically harmful visceral fat. This article reviews the current evidence, safety considerations, and how ALA fits within a broader approach to weight management.

What is alpha lipoic acid and how does it work in the body?

ALA is a naturally occurring antioxidant that functions in both water- and fat-soluble environments, supporting mitochondrial energy metabolism, regenerating other antioxidants, and potentially influencing insulin sensitivity and AMPK activity relevant to fat metabolism.

Alpha lipoic acid (ALA) is a naturally occurring antioxidant compound produced in small amounts by the body and found in foods such as spinach, broccoli, and red meat. It is both water-soluble and fat-soluble, which means it can function in a wider range of tissues than many other antioxidants, including within cells and in the bloodstream.^[1][2]

ALA plays a central role in mitochondrial energy metabolism, acting as a cofactor for enzymes involved in converting glucose into usable energy. It also helps regenerate other antioxidants, including vitamins C and E and glutathione, contributing to the body's overall defence against oxidative stress.^[1][3] These mechanisms are well described in pharmacology literature, though most detailed mechanistic evidence comes from laboratory and animal studies rather than large human trials.

Oxidative stress and chronic low-grade inflammation are increasingly recognised as factors associated with the accumulation of visceral fat, the metabolically active fat stored around the abdominal organs. Visceral fat differs from subcutaneous fat (the fat stored just beneath the skin) in that it is more closely linked to cardiometabolic risk; it is typically estimated using waist circumference in clinical practice, though imaging methods such as CT or MRI provide more direct measurement.

In supplement form, ALA is available in much higher concentrations than can be obtained through diet alone. Research has explored whether these pharmacological doses can influence metabolic pathways relevant to body weight and fat distribution. Proposed mechanisms include effects on appetite regulation via the hypothalamus, improvements in insulin sensitivity, and modulation of AMP-activated protein kinase (AMPK), an enzyme sometimes described as a cellular energy sensor.^[9][1] These mechanisms are biologically plausible and have been explored in preclinical models; their clinical significance in humans remains an active area of investigation.

What does the current evidence say about ALA and weight management?

Meta-analyses show ALA produces statistically significant but modest reductions in body weight versus placebo; direct evidence of visceral fat reduction is limited, as most trials used waist circumference rather than imaging.

Clinical trial evidence suggests that alpha lipoic acid supplementation may produce modest reductions in body weight and waist circumference, though the effects are generally small and not consistently observed across all studies. A meta-analysis published in Obesity Reviews (Kucukgoncu et al., 2017) pooled data from randomised controlled trials and found that ALA supplementation was associated with a statistically significant but modest reduction in body weight compared with placebo.^[5] Effects on visceral fat specifically were less well characterised, as many trials used waist circumference or BMI as proxy measures rather than direct imaging of visceral adipose tissue such as CT or MRI.

Some trials in people with metabolic syndrome, type 2 diabetes, or obesity have reported improvements in insulin resistance and fasting glucose alongside modest weight changes, which may be relevant given the close relationship between insulin sensitivity and visceral fat accumulation. However, study quality varies considerably, with differences in ALA dose, duration, participant characteristics, and outcome measures making direct comparisons difficult. Newer systematic reviews have not substantially changed this overall picture, and the evidence remains limited by small sample sizes and short follow-up periods.

It is important to note that ALA is not licensed by the MHRA as a medicine for weight management or visceral fat reduction. In the UK, it is sold as a food supplement, which means it is not subject to the same regulatory scrutiny as licensed medicines and does not carry an approved therapeutic indication. The evidence base, while suggestive of some metabolic benefit, is not yet sufficient to support ALA as a standalone treatment for obesity or excess visceral fat. Individuals seeking evidence-based weight management should discuss options with a healthcare professional rather than relying solely on supplements.

How much alpha lipoic acid should you take, and is it safe?

No UK-recommended dose exists; research has used 300 mg to 1,800 mg daily in supervised settings. Key risks include hypoglycaemia in people with diabetes, and ALA is not recommended in pregnancy, breastfeeding, or under-18s.

There is no officially recommended daily dose of alpha lipoic acid established by UK regulatory bodies such as the MHRA or NICE, as ALA is classified as a food supplement rather than a licensed medicine. Clinical trials investigating metabolic and weight-related outcomes have typically used doses ranging from 300 mg to 1,800 mg per day, often divided into two or three doses.^[5][6] These doses were used in supervised research settings and should not be interpreted as a general recommendation for self-supplementation.

At doses used in research, ALA is generally well tolerated by most adults. Reported side effects include:

• Nausea, vomiting, and stomach upset, particularly at higher doses

• Headache and skin rash

• A risk of hypoglycaemia (low blood sugar), especially in people taking medicines for diabetes; if you have diabetes, speak to your GP or prescriber before starting ALA, as more frequent blood glucose monitoring and possible adjustments to your diabetes medicines may be needed

• Allergic reactions, which may include rash, swelling, or difficulty breathing; if you experience these, stop taking the supplement and seek urgent medical advice

Some evidence from small studies suggests that high-dose ALA may affect thyroid hormone levels, though this has not been consistently demonstrated and the clinical relevance is uncertain.^[10] If you have a thyroid condition, discuss this with your GP before taking ALA supplements.

If you are receiving treatment for cancer, speak to your oncology team before taking any supplement, as interactions with some treatments are possible.

ALA supplements are not recommended during pregnancy or breastfeeding due to insufficient safety data; the NHS advises caution with supplements not specifically recommended by a healthcare professional during these periods.^[11] ALA supplements are also not recommended for children and young people under 18 years of age, as safety and efficacy data in this age group are lacking.

Because ALA is sold as a supplement rather than a medicine, product quality and actual ALA content can vary between brands. Choosing a product from a reputable manufacturer that follows Good Manufacturing Practice (GMP) standards is advisable.

If you experience any unexpected symptoms after starting ALA, contact your GP for advice. Suspected adverse reactions to food supplements can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Who is most likely to benefit from alpha lipoic acid supplements?

People with insulin resistance, type 2 diabetes, prediabetes, or metabolic syndrome are the most studied group, with some evidence of modest improvements in insulin sensitivity, though effect sizes are small and inconsistent.

People with metabolic conditions characterised by insulin resistance, such as type 2 diabetes, prediabetes, or metabolic syndrome, are the group most studied in relation to ALA supplementation. Some trials in these populations have reported improvements in markers of insulin sensitivity, including fasting glucose and HOMA-IR (a measure of insulin resistance), alongside modest changes in body weight. However, effect sizes have generally been small and findings are not consistent across all studies, so it would be an overstatement to say that benefit is reliably demonstrated even in these groups.

Individuals with elevated waist circumference and associated cardiovascular risk factors may also be a relevant population, given the relationship between visceral adiposity, inflammation, and metabolic dysfunction. In the UK, waist circumference thresholds associated with increased cardiometabolic risk are generally taken as above 94 cm (37 inches) for men and above 80 cm (31.5 inches) for women, with higher risk above 102 cm and 88 cm respectively; lower thresholds apply for people of South Asian, Chinese, Japanese, and some other ethnic backgrounds. Your GP can advise on what these measurements mean for your individual risk.

It is important to emphasise that the evidence does not support ALA as a primary treatment for any of these conditions, and it should not replace lifestyle interventions or prescribed medicines.

ALA is unlikely to offer meaningful benefit to people who are already metabolically healthy and at a healthy weight. The supplement is not a substitute for a balanced diet, regular physical activity, or, where clinically appropriate, licensed weight management medicines.

For those considering a structured approach to weight management, a range of options exists, from lifestyle programmes to pharmacological treatments. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options can be discussed. Anyone with significant excess weight, particularly with associated health conditions, should seek a formal assessment from their GP or a specialist weight management service, as NICE guidance supports a comprehensive, individualised approach to treatment.

What else can help reduce visceral fat alongside ALA?

The most evidence-based strategies are sustained caloric deficit, Mediterranean-style diet, regular aerobic and resistance exercise, and, for eligible individuals, licensed GLP-1 receptor agonist medicines prescribed following clinical assessment.

Reducing visceral fat effectively requires a combination of approaches, and no single supplement, including alpha lipoic acid, is sufficient on its own. The most robustly evidenced strategies for reducing visceral adiposity include sustained caloric deficit through dietary change, regular aerobic exercise, and, where appropriate, pharmacological support.

Dietary approaches with the strongest evidence include:

• A Mediterranean-style diet rich in vegetables, legumes, whole grains, fish, and unsaturated fats; the British Dietetic Association and NHS both recognise this pattern as supportive of cardiovascular and metabolic health

• Reducing ultra-processed foods, added sugars, and refined carbohydrates

• Adequate dietary protein to support lean mass during weight loss

Physical activity is particularly effective at reducing visceral fat, even in the absence of significant overall weight loss. Both aerobic exercise (such as brisk walking, cycling, or swimming) and resistance training have demonstrated benefits. The UK Chief Medical Officers' Physical Activity Guidelines for adults recommend at least 150 minutes of moderate-intensity activity per week, and this is also reflected in NHS guidance on weight management.^[14][15]

Sleep and stress management are increasingly recognised as relevant factors. Chronic sleep deprivation and elevated cortisol from psychological stress are associated with greater visceral fat deposition, and addressing these may support other interventions.^[21]

Licensed pharmacological treatments, such as GLP-1 receptor agonists, are available for eligible individuals and have demonstrated clinically meaningful reductions in body weight in clinical trials, with imaging substudies in some programmes suggesting reductions in visceral adipose tissue.^[19][20] These are prescription-only medicines subject to MHRA authorisation and NICE technology appraisal guidance, and access depends on individual clinical assessment and local ICB commissioning decisions.

If you are concerned about visceral fat and its health implications, speaking to your GP is the most appropriate first step to explore a personalised, evidence-based management plan.

Scientific References

1. Alpha-Lipoic Acid: Biological Mechanisms and Health Benefits. Antioxidants (Basel)..
2. α-Lipoic acid: from a mitochondrial cofactor to a versatile platform for dynamic biomaterials and translational biomedicine. Chemical Society Reviews..
3. Endogenous ascorbate regenerates vitamin E in the retina directly and in combination with exogenous dihydrolipoic acid. Current Eye Research..
4. α-lipoic acid ameliorates consequences of copper overload by up-regulating selenoproteins and decreasing redox misbalance. PNAS..
5. Alpha-lipoic acid (ALA) as a supplementation for weight loss. Obesity Reviews. Kucukgoncu et al..
6. Alpha-lipoic acid supplement in obesity treatment: A systematic review and meta-analysis of clinical trials. Namazi et al..
7. Appendix A2: Summary of evidence from surveillance (NG246) — includes ALA in obesity treatment. NICE..
8. Medicines: licensing and applications — GOV.UK.
9. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways..
10. Effect of alpha-lipoic acid on the peripheral conversion of thyroxine to triiodothyronine and on serum lipid-, protein- and glucose levels..
11. Use of medicines in pregnancy and breastfeeding — GOV.UK.
12. Identifying and assessing overweight, obesity and central adiposity (NG246). NICE..
13. PH46 Expert report 1: ADDITION-Leicester Study — ethnic-specific BMI and waist circumference thresholds. NICE..
14. Physical activity guidelines: UK Chief Medical Officers' report. GOV.UK..
15. Physical activity guidelines for adults aged 19 to 64. NHS..
16. Impact of Different Exercise Modalities on Visceral Adipose Tissue in Normal Weight and Low-Overweight Individuals: A Systematic Review and Meta-Analysis. Biological Research for Nursing..
17. Aerobic Exercise and Weight Loss in Adults — dose-response meta-analysis of 116 RCTs..
18. The Effect of Resistance Training in Healthy Adults on Body Fat — systematic review and meta-analysis..
19. GLP-1 medicines for weight loss and diabetes: what you need to know. GOV.UK..
20. Summary of NICE guidance for GLP-1 receptor agonists and tirzepatide in adults. NICE..
21. Stress-induced cortisol secretion is consistently greater among women with central fat. Epel et al. Psychosomatic Medicine..

Frequently Asked Questions